On May 8, 1945, the Allied Forces accepted the unconditional surrender of Adolf Hitler’s Nazi armed forces, officially marking the end of Hitler’s Third Reich.
In 2004, the United Nations declared May 8 and 9 annually as an International Time of Remembrance and Reconciliation for Those Who Lost Their Lives During the Second World War.
Honouring Lives Lost & Those Who Fought for Freedom
During World War II (WWII), it is estimated that a total of anywhere from 70 million to upwards of 85 million people lost their lives, whether as soldiers or civilians. Of this incomprehensible number, a total of 40 million civilians lost their lives, including the 6 million Jews that perished during the Holocaust.
Over 20 million soldiers fought to their death on a global scale, among those being
45,400 Canadian soldiers, with Canada entering the war in 1939, two years before the U.S. entered after Pearl Harbor.
Of the one million Canadian soldiers who served during WWII, 33,200 veterans are still alive to this day, and still bear the scars of their service to Canada and the world. We seek to honour these veterans, of WWII, and all wars that Canadians have fought in by educating veterans about medical cannabis, while helping them access high-quality
cannabis at compassionate pricing.
Veterans & Post Traumatic Stress Disorder
One of the scars that soldiers in all wars have to bear is Post Traumatic Stress Disorder (PTSD), sometimes referred to as Post Traumatic Stress (PTS) injury. Back in WWII era, psychology, unfortunately, didn’t have the nomenclature to property term the condition that commonly affected soldiers, being referred to as “soldier’s heart” or “shell shock” or “war neurosis” until it was adequately termed as Post Traumatic Stress Disorder in the 1980s. It’s estimated to have affected a minimum of 10% of Canada’s veterans over time, although this seems to be a conservative number.
PTSD or PTS, according to the Canadian Mental Health Association, is a mental illness characterized by exposure to trauma and traumatic events involving death, or the threat of death, serious injury, or sexual violence. PTSD causes intrusive symptoms such as re- experiencing an event, which manifests in different ways. Many people have vivid nightmares, flashbacks, or thoughts of the event that can sometimes seemingly come out of nowhere, leading the person to avoid things that remind them of the event. With many experiencing a change in mood and losing the ability to cope, it’s common for some with PTSD to turn to drugs or alcohol.
Since medical cannabis became accessible in Canada, Veterans Affairs Canada has
supported Canadian veterans in acquiring medical cannabis documents and medical cannabis for PTSD. The increased global uptake on cannabis for PTSD is underscored by an evidence-based approach to how cannabis may affect those living with PTSD.
PTSD & The Endocannabinoid System (ECS)
Much of the research on PTSD and cannabis hinges on the endocannabinoid system
(ECS), a whole-body system that is responsible for regulating the most important
physiological processes for establishing and maintaining mammalian health. Although
rather new in its discovery, the endocannabinoid system is increasing in medical
sciences as an important and crucial bodily system, with endogenous cannabinoids
(originating from within the body) being a regulator of the ECS. A 2009 review of the
literature connecting the endocannabinoid system and mood and anxiety disorders
concluded, the “growing body of evidence unequivocally demonstrates that deficits in
endocannabinoid signaling may result in depressive and anxiogenic behavioral
The term endocannabinoid deficiency syndrome (CEDS) was coined in 2003 by Dr.
Ethan Russo and describes a lack of endocannabinoid activity in the brain.
Endocannabinoid deficiency is said to be linked to medical conditions such as
fibromyalgia, chronic migraines, Multiple Sclerosis (MS), seizure disorders, chronic
fatigue, irritable bowel syndrome, and mood disorders, including PTSD. Stimulation of
the cannabinoid receptors via phytocannabinoids (plant-based cannabinoids, most
commonly derived from cannabis) are being researched for their ability to increase
stress coping behaviors, including the regulation of serotonin.
Cannabis & Anadamide
Researchers are examining the connection between PTSD, cannabinoids, and anandamide (“the bliss molecule”) in the amygdala, which is the part of the brain
responsible for emotions, and the controlling of aggression. They hypothesize that
augmenting levels of anandamide in the amygdala modulates short-term fear extinction,
resulting in long-term reduction on fear-based responses, or the natural “fight or flight”
mode. The brain’s hippocampus contains a high density of CB1 receptors, which along
with the CB2 is a critical component of the endocannabinoid system. Researchers are
examining how THC mimics anandamide and how it binds to the cannabinoid receptors
in the brain, and thus regulate mood.
In the context of PTSD, a 2015 study on mice found that high levels of anandamide were
catalysts for fear-reduction and mood enhancement. THC is responsible for altering
normal brain signals and processes, which leads to the psychoactive effects. When THC
is consumed, it increases the number of cannabinoids in the endocannabinoid system,
which alters communications between neurons. Anandamide plays a role in these
Cannabis & Sleep Disturbances
Many people living with PTSD live with nightmares, insomnia, and other sleep disorders, which leads to a decline in mental stability in the long-term. A 2009 study
looking at synthetic cannabinoids showed that 72% of those who received the
cannabinoids experienced a cessation of or noted lessening of the severity of
nightmares. As such, cannabinoids are being sought out as an alternative to powerful
pharmaceutical and over-the-counter medications that induce sleep.
Access to Cannabis for Veterans
In light of the research supporting cannabis for veterans and PTSD, and the leadership
of Veterans Affairs Canada to cover most medical cannabis expenses for veterans, JC
Green wanted to be a part of the initiatives that make access easy for this specific
The Time of Remembrance and Reconciliation for Those Who Lost Their Lives During
the Second World War, to us, is not only a time to honour and remember the past, but
also honour and look towards our present, and our future by caring for those who have
JC Green, and our medical cannabis affiliate brand JC Medicinal, serves all Canadians
in the safe, convenient, and legal acquisition of medical cannabis intended to increase
quality of life. For veterans, we offer compassionate pricing that makes the price of high-
quality cannabis of superior genetics more affordable.
Veterans are invited to connect with our affiliate medical cannabis clinic, Karthia, to be
connected with a health practitioner and a Patient Services Team to explore options for
medical cannabis and eligibility for compassionate pricing.
More information about Karthia can be found at https://karthia.ca/, and the clinic can
be accessed directly by calling 1-833-222-6777
, or emailing firstname.lastname@example.org
Medicinal’s superior quality products can be viewed at
Signup to learn more about Medical Cannabis
Dincheva, I., Drysdale, A. T., Hartley, C. A., Johnson, D. C., Jing, D., King, E. C., … &
Huang, C. (2015). FAAH genetic variation enhances fronto-amygdala function in mouse
and human. Nature communications, 6, 6395.
Fraser, G. A. (2009). The use of a synthetic cannabinoid in the management of
treatment‐resistant nightmares in posttraumatic stress disorder (PTSD). CNS
neuroscience & therapeutics, 15(1), 84-88.
Neumeister, A., Normandin, M. D., Pietrzak, R. H., Piomelli, D., Zheng, M. Q., Gujarro-
Anton, A., … & Ropchan, J. (2013). Elevated brain cannabinoid CB 1 receptor availability
in post-traumatic stress disorder: a positron emission tomography study. Molecular
psychiatry, 18(9), 1034.
Shishko, I., Oliveira, R., Moore, T. A., & Almeida, K. (2018). A review of medical
marijuana for the treatment of posttraumatic stress disorder: Real symptom re-leaf or
just high hopes?. Mental Health Clinician, 8(2), 86-94.